148 related articles for article (PubMed ID: 38086194)
1. Biological evaluation of carbohydrate-based aprepitant analogs for neuroblastoma treatment.
Valdivia V; Recio R; Lerena P; Pozo E; Serrano R; Calero R; Pintado C; Leal MP; Moreno-Rodríguez N; Organero JÁ; Khiar N; Fernández I
Eur J Med Chem; 2024 Jan; 264():116021. PubMed ID: 38086194
[TBL] [Abstract][Full Text] [Related]
2. Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity.
Recio R; Lerena P; Pozo E; Calderón-Montaño JM; Burgos-Morón E; López-Lázaro M; Valdivia V; Pernia Leal M; Mouillac B; Organero JÁ; Khiar N; Fernández I
J Med Chem; 2021 Jul; 64(14):10350-10370. PubMed ID: 34236855
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells.
Dikmen M; Gökhaner G; Cantürk Z
Anticancer Drugs; 2019 Aug; 30(7):e0769. PubMed ID: 31306152
[TBL] [Abstract][Full Text] [Related]
4. Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting.
Van Belle SJ; Cocquyt V
Expert Opin Pharmacother; 2008 Dec; 9(18):3261-70. PubMed ID: 19040346
[TBL] [Abstract][Full Text] [Related]
5. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
6. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
[TBL] [Abstract][Full Text] [Related]
7. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Opin Investig Drugs; 2007 Dec; 16(12):1977-85. PubMed ID: 18042005
[TBL] [Abstract][Full Text] [Related]
8. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
[TBL] [Abstract][Full Text] [Related]
9. Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting.
Girish C; Manikandan S
Indian J Cancer; 2007; 44(1):25-30. PubMed ID: 17401221
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic evaluation of fosaprepitant dimeglumine.
Colon-Gonzalez F; Kraft WK
Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1277-86. PubMed ID: 20795794
[TBL] [Abstract][Full Text] [Related]
11. Drug-drug interactions with aprepitant in antiemetic prophylaxis for chemotherapy.
Schoffelen R; Lankheet AG; van Herpen CML; van der Hoeven JJM; Desar IME; Kramers C
Neth J Med; 2018 Apr; 76(3):109-114. PubMed ID: 29667586
[TBL] [Abstract][Full Text] [Related]
12. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
13. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging.
Van Laere K; De Hoon J; Bormans G; Koole M; Derdelinckx I; De Lepeleire I; Declercq R; Sanabria Bohorquez SM; Hamill T; Mozley PD; Tatosian D; Xie W; Liu Y; Liu F; Zappacosta P; Mahon C; Butterfield KL; Rosen LB; Murphy MG; Hargreaves RJ; Wagner JA; Shadle CR
Clin Pharmacol Ther; 2012 Aug; 92(2):243-50. PubMed ID: 22739139
[TBL] [Abstract][Full Text] [Related]
14. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.
Burns D; Kula J; Marshall S; Ashworth E; Ornelas M
Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650
[TBL] [Abstract][Full Text] [Related]
15. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
Aapro M; Carides A; Rapoport BL; Schmoll HJ; Zhang L; Warr D
Oncologist; 2015 Apr; 20(4):450-8. PubMed ID: 25795636
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of aprepitant and fosaprepitant in pediatric patients.
Saito Y; Kumamoto T; Arima T; Shirakawa N; Ishimaru S; Sonoda T; Nakajima M; Sugiyama M; Arakawa A; Hashimoto H; Makino Y; Ogawa C; Yamaguchi M
Pediatr Int; 2019 Mar; 61(3):235-239. PubMed ID: 30615239
[TBL] [Abstract][Full Text] [Related]
17. IV aprepitant (Cinvanti) for chemotherapy-induced nausea and vomiting.
Med Lett Drugs Ther; 2018 Dec; 60(1561):e200-e201. PubMed ID: 30653479
[No Abstract] [Full Text] [Related]
18. Aprepitant Promotes Caspase-Dependent Apoptotic Cell Death and G2/M Arrest through PI3K/Akt/NF-
Javid H; Afshari AR; Zahedi Avval F; Asadi J; Hashemy SI
Biomed Res Int; 2021; 2021():8808214. PubMed ID: 34926694
[TBL] [Abstract][Full Text] [Related]
19. Aprepitant--a novel NK1-receptor antagonist.
Patel L; Lindley C
Expert Opin Pharmacother; 2003 Dec; 4(12):2279-96. PubMed ID: 14640927
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer.
Ikeda M; Shida M; Hirasawa T; Muramatsu T; Mikami M
J Obstet Gynaecol Res; 2017 Oct; 43(10):1613-1620. PubMed ID: 28691209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
